Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2026 08:00 ET | Source: Brain Cancer Canada

Brain Cancer Canada Invests $75,000 in Groundbreaking Phase 2 Clinical Trial at Sunnybrook Health Sciences Centre to Target Hard-to-Treat Glioblastoma in Older Patients

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide to award $75,000 to...
May 12, 2026 08:00 ET | Source: Brain Cancer Canada

Brain Cancer Canada Awards $100,000 “The Emily McIntosh Brain Cancer Research Grant” to Advance Breakthrough Immunotherapy for Glioblastoma

TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), Canada’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide is proud to...
May 11, 2026 07:00 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since...
May 08, 2026 09:10 ET | Source: Alpha Tau Medical Ltd.

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
April 21, 2026 09:00 ET | Source: Brain Cancer Canada

Brain Cancer Canada Marks Brain Cancer Awareness Month in May with National Landmark Lightings, Community Events, New Research Investments, and a Call to Action

Awareness eventsResearch grant awardsGala for Brain Cancer Research with Catherine Wreford and Dr. Cynthia Hawkins TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), the only...
April 02, 2026 07:01 ET | Source: Research and Markets

Low-Grade Glioma Market Trends and Investment Opportunities Through 2030 & 2035: Regional Insights for Trametinib, Dabrafenib, Ivosidenib, and Mirdametinib

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Low-Grade Glioma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global low-grade glioma market is experiencing a...
February 24, 2026 10:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma

Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
February 04, 2026 04:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit

Highlights: Strategic Validation: Industry feedback confirms Rakovina’s approach targeting PTEN-deficient tumours with brain-penetrant ATR/mTOR inhibitors addresses critical gaps left by recent...
January 08, 2026 04:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies...
October 17, 2025 11:53 ET | Source: Azurity Pharmaceuticals

Azurity Pharmaceuticals Announces the FDA Approval of Ferabright<sup>TM</sup> (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the Brain

Woburn, MA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the...